Sebastián-Pérez, V.; García-Rubia, A.; Seif el-Din, S. H.; Sabra, A.-N. A.; El-Lakkany, N. M.; William, S.; Blundell, T. L.; Maes, L.; Martinez, A.; Campillo, N. E.; Botros, S. S.; Gil, C.  [2020]. Deciphering the enzymatic target of a new family of antischistosomal agents bearing a quinazoline scaffold using complementary computational tools. J. Enz. Inh. Med. Chem. 2020, 35, 511-523.

Martínez de Iturrate, P.; Sebastián-Pérez, V.; Nácher-Vázquez, M.; Tremper, C. S.; Smirlis, D.; Martin, J.; Martínez, A.; Campillo, N. E.; Rivas, L.; Gil, C.  [2020]. Towards discovery of new leishmanicidal scaffolds able to inhibit Leishmania GSK-3. J. Enz. Inh. Med. Chem. 2020,35, 199-210.

Botros, S. S.; Williams, S.; Sabra, A-N. A.; El-Lakkany, N. M.; Seif el-Din, S. H.; Sterk, G. J.; Salado, I. G.; Augustyns, K.; García-Rubia, A.; Sebastian-Perez, V.; Maes, L.; Munday, J. C.; Leurs, R.; Gil, C.; De Koning, H. P  [2019]. Antischistosomal screening of a PDE-focused library identifies imidazoles with in vitro and in vivo activity. Int. J. Parasitol.: Drugs Drug Resist. 2019, 9, 35-43.

de Araújo, J. S.; Garcia-Rubia, A.; Sebastian-Perez, V.; Kalejaiye, T. D.; Bernardino da Silva, P.; Fonseca-Berzal, C. R.; Maes, L.; De Koning, H.; Soeiro, M. N. C.; Gil, C.  [2019]. Imidazole derivatives as promising agents for the treatment of Chagas disease. Antimicrob. Agents Chemother. 2019, 63, e02156-18.

Sebastián-Pérez, V.; Martinez, M. J.; Gil, C.; Campillo, N. E.; Martinez, A.; Ponzoni, I.  [2019]. Inference of QSAR Models for identifying LRRK2 inhibitors for the treatment of Parkinson’s Disease. J. Integr. Bioinform. 2019, 20180063.

Martinez, A.; Gil, C.  [2019]. “Protein kinase inhibitors for the treatment of Multiple Sclerosis” en Emerging Drugs and Targets for Multiple Sclerosis. Ed. A. Martínez, Royal Society of Chemistry. 2019, 170-196.

Sebastian-Pérez, V.; Schroeder, S.; Munday, J. C.; van der Meer, T.; Zaldívar-Díez, J.; Siderius, M.; de Koning, H. P.; Brown, D.; Martinez, A.; Campillo, N. E.; Leurs, R.; Gil, C.  [2019]. Discovery of novel Schistosoma mansoni SmPDE4A inhibitors as potential agents against schistosomiasis. Fut. Med. Chem. 2019, 11, 1703-1720.

Ponzoni, I.; Sebastian-Perez, V.; Martinez, M. J.; Roca, C.; De la Cruz, C.; Perez, C.; Cravero, F.; Vazquez, G.; Paez, J. A.; Diaz, M. F.; Campillo, N. E.  [2019]. QSAR classification models for predicting the activity of inhibitors of Beta-Secretase (BACE1) associated with Alzheimer's disease. Sci. Rep. 2019, 9, 9102.

Posa, D.; Martinez-Gonzalez, L.; Bartolome, F.; Nagaraj, S.; Porras, G.; Martinez, A.; Martin-Requero, A.  [2018]. Recapitulation of pathological TDP-43 features in immortalized lymphocytes from sporadic ALS patients. Mol. Neurobiol. 2018, doi: 10.1007/s12035-018-1249-8.

Kraft, C.; Boya, P.; Codogno, P.; Elazar, Z.; Eskelinen, E. L.; Farres, J.; Kirkin, V.; Jungbluth, H.; Martinez, A.; Pless, O.; Primard, C.; Proikas-Cezanne, T.; Simonsen, A.; Reggiori, F.  [2018]. Driving next-generation autophagy researchers towards translation (DRIVE), an international PhD training program on autophagy. Autophagy 2018, 1-5.

Decara, J.; Serrano, A.; Pavon, F. J.; Rivera, P.; Arco, R.; Gavito, A.; Vargas, A.; Navarro, J. A.; Tovar, R.; Lopez-Gambero, A. J.; Martinez, A.; Suarez, J.; Rodriguez de Fonseca, F.; Baixeras, E.  [2018]. The adiponectin promoter activator NP-1 induces high levels of circulating TNFalpha and weight loss in obese (fa/fa) Zucker rats. Sci. Rep. 2018, 8, 9858.

Cheng, Y.; Desse, S.; Martinez, A.; Worthen, R. J.; Jope, R. S.; Beurel, E.  [2018]. TNFalpha disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice. Brain Behav. Immun. 2018, 69, 556-567.

Benek, O.; Hroch, L.; Aitken, L.; Gunn-Moore, F.; Vinklarova, L.; Kuca, K.; Perez, D. I.; Perez, C.; Martinez, A.; Fisar, Z.; Musilek, K.  [2018]. 1-(Benzo[d]thiazol-2-yl)-3-phenylureas as dual inhibitors of casein kinase 1 and ABAD enzymes for treatment of neurodegenerative disorders. J. Enzyme Inhib. Med. Chem. 2018, 33, 665-670.

Alten, B.; Yesiltepe, M.; Bayraktar, E.; Tas, S. T.; Gocmen, A. Y.; Kursungoz, C.; Martinez, A.; Sara, Y.  [2018]. High-fructose corn syrup consumption in adolescent rats causes bipolar-like behavioural phenotype with hyperexcitability in hippocampal CA3-CA1 synapses. Br. J. Pharmacol. 2018, 175, 4450-4463.

Sebastián-Pérez, V.; Hendrickx, S.; Munday, J. C.; Kalejaiye, T.; Martínez, A.; Campillo, N. E.; de Koning, H.; Caljon, G.; Maes, L.; Gil, C.  [2018]. Cyclic nucleotide specific phosphodiesterases as potential drug targets for anti-Leishmania therapy. Antimicrob. Agents Chemother. 2018, 62, e00603-18.

Chierrito, T. P. C.; Pedersoli-Mantoani, S.; Roca, C.; Sebastian-Perez, V.; Martinez-Gonzalez, L.; Perez, D. I.; Perez, C.; Canales, A.; Cañada, F. J.; Campillo, N. E.; Carvalho, I.; Martinez, A.  [2018]. Chameleon-like behavior of indolylpiperidines in complex with cholinesterases targets: Potent butyrylcholinesterase inhibitors. Eur. J. Med. Chem. 2018, 145, 431-444.

Paez, J. A.; Campillo, N. E.  [2018]. Innovative therapeutic potential of cannabinoid receptors as targets in Alzheimer's disease and less well-known diseases. Curr. Med. Chem., 2018, 25, 1-38.

Del Cerro, P.; Alquezar, C.; Bartolome, F.; Gonzalez-Naranjo, P.; Perez, C.; Carro, E.; Paez, J. A.; Campillo, N. E.; Martin-Requero, A.  [2018]. Activation of the cannabinoid type 2 receptor by a novel indazole derivative normalizes the survival pattern of lymphoblasts from patients with late-onset Alzheimer's disease. CNS Drugs 2018, 32, 579-591.

Roca, C.; Requena, C.; Sebastian-Perez, V.; Malhotra, S.; Radoux, C.; Perez, C.; Martinez, A.; Antonio Paez, J.; Blundell, T. L.; Campillo, N. E.  [2018]. . Identification of new allosteric sites and modulators of AChE through computational and experimental tools. J. Enzyme Inhib. Med. Chem. 2018, 33, 1034-1047.

Gandini, A.; Bartolini, M.; Tedesco, D.; Martinez-Gonzalez, L.; Roca, C.; Campillo, N. E.; Zaldivar-Diez, J.; Perez, C.; Zuccheri, G.; Miti, A.; Petralla, A.; Monti, B.; Rossi, M.; Moda, F.; Legname, G.; Martinez, A.; Bolognesi, M. L.  [2018]. Tau-centric multitarget approach for Alzheimer's disease: Development of first-in-class dual Glycogen Synthase Kinase 3beta and tau-aggregation inhibitors. J. Med. Chem. 2018, 61, 7640-7656.